ARKG vs XBI

Key Takeaways

• ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund focused on the genomics revolution, while SPDR S&P Biotech ETF (XBI) is a passively managed equal-weighted index fund tracking the broader biotechnology sector.
• ARKG maintains a concentrated portfolio of approximately 30-60 holdings with high active share, whereas XBI holds around 160 stocks for greater diversification within biotechnology.
• Expense ratios differ significantly, with ARKG at 0.75% and XBI at 0.35%, reflecting the active versus passive management approaches.
• Both ETFs target healthcare innovation but differ in strategy: ARKG emphasizes genomics-specific themes across multiple sectors, while XBI provides broad exposure to U.S. biotechnology companies via a modified equal-weighted index.
• Liquidity profiles favor XBI due to higher average daily trading volume and larger assets under management compared to ARKG.
• Structural differences position ARKG for higher-conviction thematic bets and XBI for cost-efficient sector rotation within biotech.

Introduction

Investors seeking exposure to biotechnology and genomics innovation often compare ARK Genomic Revolution ETF (ARKG) and SPDR S&P Biotech ETF (XBI). These funds do not compete directly as identical products but offer alternative strategies within the same healthcare sector. ARKG pursues an active, thematic approach centered on the genomics revolution, while XBI delivers passive, broad-based biotechnology exposure through an index. The comparison highlights differences in management style, diversification, costs, and positioning, helping investors align selections with risk tolerance and objectives in a sector driven by scientific advancements and regulatory developments.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014. It seeks long-term capital growth by investing at least 80% of assets in equity securities of companies relevant to the genomics revolution theme, spanning healthcare, information technology, materials, energy, and consumer discretionary sectors. The fund typically holds 30-60 positions with a non-diversified structure and high active share. Recent top holdings include 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Absci Corp (ABSI). Sector allocation centers heavily on healthcare, particularly genomics and life sciences tools. The expense ratio stands at 0.75%. Management involves ongoing rebalancing based on ARK Investment Management's research-driven process rather than a fixed index.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) is a passively managed fund launched in 2006 that seeks to track the total return of the S&P Biotechnology Select Industry Index. This modified equal-weighted index covers the biotechnology segment of the S&P Total Market Index. The ETF holds approximately 160 stocks, providing broad diversification across U.S. biotechnology companies. Top holdings typically include Twist Bioscience Corp (TWST), Moderna Inc (MRNA), Natera Inc (NTRA), and other mid- and small-cap biotechs, with each position capped near equal weight. Nearly all assets reside in healthcare, primarily biotechnology. The expense ratio is 0.35%. The fund employs a sampling strategy for efficient replication and quarterly rebalancing aligned with index methodology, resulting in higher liquidity from substantial assets under management and trading volume.

Industry and Thematic Backdrop

The biotechnology and genomics sectors operate in a dynamic environment shaped by scientific breakthroughs in gene editing, precision medicine, and bioinformatics. Macroeconomic factors such as interest rate expectations influence capital allocation to growth-oriented healthcare companies, while regulatory pathways for novel therapies and potential policy shifts on drug pricing remain key variables. Capital flows into innovation-driven subsectors continue amid ongoing research and development cycles. Risks include clinical trial outcomes, intellectual property challenges, and sector-specific volatility tied to earnings from top holdings. Both ETFs reflect exposure to these themes, though through distinct lenses of active thematic selection versus broad index participation.

Performance and Positioning Comparison

In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited higher volatility due to its concentrated active bets on genomics innovators, leading to sharper swings during sector rotations or shifts in risk appetite. SPDR S&P Biotech ETF (XBI) has demonstrated more moderated movements through equal weighting, which reduces concentration risk and supports steadier participation across the biotechnology universe. Relative positioning shows ARKG tilting toward smaller, high-growth genomics names, while XBI balances exposure across clinical-stage and commercial biotechs. Performance differences in recent weeks and months connect to broader healthcare earnings trends, interest rate sensitivity, and momentum in gene therapy advancements, with XBI's lower costs and diversification often providing a buffer in uncertain environments.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore current opportunities in biotechnology and genomics sectors.

Tickeron AI Verdict

Based on observable structural factors including lower expense ratio, broader diversification across approximately 160 holdings, and passive replication of a liquid index, Tickeron’s AI would currently assign higher probabilistic favor to SPDR S&P Biotech ETF (XBI) for investors prioritizing cost efficiency and risk-managed sector exposure. ARK Genomic Revolution ETF (ARKG) offers compelling active thematic depth for those seeking concentrated genomics bets, though its higher fees and concentration warrant careful consideration of risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations